

# Vascular Endothelial Growth Factor Mediates Angiogenic Activity during the Proliferative Phase of Wound Healing

Nicholas N. Nissen,\* Peter J. Polverini,<sup>†</sup>  
Alisa E. Koch,<sup>‡§</sup> Michael V. Volin,<sup>‡</sup>  
Richard L. Gamelli,\* and Luisa A. DiPietro\*

From the Department of Surgery,\* Burn and Shock Trauma Institute, Loyola University Medical Center, Maywood, Illinois, the Laboratory of Molecular Pathology,<sup>†</sup> University of Michigan, Ann Arbor, Michigan, the Department of Medicine,<sup>‡</sup> Northwestern University Medical Center, Chicago, Illinois, and the Veteran's Administration Chicago Health Care System,<sup>§</sup> Lakeside Division, Chicago, Illinois

Angiogenesis is an essential component of normal wound repair, yet the primary mediators of wound angiogenesis have not been well described. The current study characterizes the contribution of vascular endothelial cell growth factor (VEGF) to the angiogenic environment of human surgical wounds. Surgical wound fluid samples ( $n = 70$ ) were collected daily for up to 7 postoperative days (POD) from 14 patients undergoing mastectomy or neck dissection. VEGF levels in surgical wound fluid were lowest on POD 0, approximating values of serum, but increased steadily through POD 7. An opposite pattern was noted for basic fibroblast growth factor-2. Fibroblast growth factor-2, which has been previously described as a wound angiogenic factor, exhibited highest levels at POD 0, declining to near serum levels by POD 3. Surgical wound fluid from all time points stimulated marked endothelial cell chemotaxis and induced a brisk neovascular response in the rat corneal micro-pocket angiogenesis assay. Antibody neutralization of VEGF did not affect the *in vitro* chemotactic or the *in vivo* angiogenic activity early wound samples (POD 0). In contrast, VEGF neutralization significantly attenuated both chemotactic activity (mean decrease  $76 \pm 13\%$ ,  $P < 0.01$ ) and angiogenic activity (5 of 5 samples affected) of later wound samples (POD 3 and 6). The results suggest a model of wound angiogenesis in which an initial angiogenic stimulus is supplied by fibroblast growth factor-2, followed by a subsequent and more prolonged angiogenic stimulus mediated by VEGF. (*Am J Pathol* 1998, 152:1445-1452)

Normal wound repair includes a vigorous angiogenic response that delivers nutrients and inflammatory cells to injured tissue. This angiogenic response facilitates the removal of debris and assists in the development of a granulation tissue framework for wound closure.<sup>1</sup> The mediators of wound angiogenesis are thought to include numerous soluble factors that have been identified in various wound models.<sup>2,3</sup> Both angiogenic agonists and antagonists have been identified at various times during repair,<sup>4,5</sup> suggesting that the net angiogenic stimulus may change as the balance of factors alternatively favors either vessel growth or regression.<sup>6,7</sup> Despite a large body of literature describing the production of angiogenic growth factors in wounds, few previous studies have attempted to determine which factors are critical mediators in healing wounds or to understand their temporal relationship to one another.

To better understand the mechanism of wound angiogenesis, recent efforts in our laboratory have been directed at identifying the soluble proangiogenic factors that are important to normal wound healing. As part of this undertaking, the angiogenic profile of fluid collected from human surgical wound drains placed at the time of various operations has been characterized.<sup>8</sup> These studies are based on the premise that wound fluid would be generally representative of the growth environment of the wound, as it would be expected to contain soluble proangiogenic growth factors at levels similar to that of the wound bed itself. While the proliferative capacity of wound fluid has been previously reported, studies of the net angiogenic stimulus in this fluid<sup>9</sup> and of the specific mediators responsible for this stimulus are incomplete.

In a previous report from our laboratory, surgical wound fluid (SWF) collected within just a few hours of operation was found to be potently angiogenic. This fluid stimulates endothelial cell migration and proliferation *in vitro* and new vessel formation in the *in vivo* rat corneal assay.<sup>8</sup> The angiogenic activity of early wound fluid was

Supported by NIH Grants GM50875 (L. A. DiPietro), HL39926 (P. J. Polverini), CA 64416 (P. J. Polverini), AR30692 (A. E. Koch), and AR41492 (A. E. Koch). Funds from the Veteran's Administration Research Service (A. E. Koch), and the Ralph and Marion Falk Foundation (A. E. Koch, N. N. Nissen, and L. A. DiPietro).

Accepted for publication March 11, 1998.

Address reprint requests to Dr. Luisa A. DiPietro, Burn and Shock Trauma Institute, Loyola University Medical Center, 2160 S. First Avenue, Maywood, IL 60153. E-mail: ldipiet@luc.edu.

found to be largely because of basic fibroblast growth factor (FGF-2). FGF-2 levels in SWF peaked immediately after surgery and then fell to near-serum levels by the second postoperative day. Thus FGF-2, stored either within cells or sequestered in the extracellular matrix, is released shortly after tissue injury. This quick release of FGF-2 appears to function to initiate wound angiogenesis. The current study was designed to identify the primary angiogenic mediators in later wounds during the proliferative phase. To accomplish this, wound fluid was collected from surgical wounds for up to 7 days postoperatively. This fluid was used to assess the role of particular growth factors as critical angiogenic mediators in human wounds. Among the many mediators in the later wound fluid, our studies quickly focused on vascular endothelial cell growth factor (VEGF) for two specific reasons. First, like FGF-2, VEGF is a potent direct angiogenic factor that stimulates endothelial cell migration and activation *in vitro* and angiogenesis *in vivo*.<sup>10,11</sup> Secondly, an up-regulation of VEGF production in wound repair has been demonstrated in keratinocytes in skin wounds in rat, guinea pig, and mouse models.<sup>12,13</sup> The current study describes the contribution of VEGF to the angiogenic activity within wounds and establishes an important role for VEGF as a predominate angiogenic mediator in human surgical wounds.

## Materials and Methods

### Patients

Surgical wound fluid was collected from 14 patients undergoing modified radical mastectomy ( $n = 8$ ) or neck dissection ( $n = 6$ ). This group consisted of 11 females and 3 males and averaged  $60 \pm 14$  years of age. A total of 70 samples were collected between postoperative days 0 and 7. Most samples collected beyond 4 days were from neck dissections because of the tendency to remove drains earlier from mastectomy sites as compared with neck procedures. No wounds were complicated by hematoma formation, infection, or flap necrosis. Breast biopsy specimens were obtained from 4 patients undergoing mastectomy 7, 8, 10, and 22 days after initial biopsy. No patient had received heparin, corticosteroids, or preoperative chemotherapy or radiation therapy before or during the time of sample collection. No patients had complicating disease processes that might affect wound healing, such as diabetes mellitus.

### Wound Fluid Samples

Surgical wound fluid was collected from closed suction drains of patients undergoing either modified radical mastectomy or neck dissections. Neck dissections were usually performed in combination with a pharyngectomy or laryngectomy. On Postoperative day (POD) 0, fluid was collected within 6 hours of surgery. Subsequent samples were obtained daily until patients were discharged or drains were removed. Occasionally patients were unavailable during the collection period and a daily

sample was not obtained. Fluid samples were processed immediately after collection by centrifuging at  $1300 \times g$  for 10 minutes and then freezing at  $-70^\circ\text{C}$ . Normal serum was obtained from volunteers and was processed as described for SWF samples. When subsets of patient samples were used in additional assays, samples were selected randomly. The average total protein content of the wound fluids was  $17 \pm 4$  mg/ml.

### VEGF and FGF-2 Enzyme-Linked Immunosorbent Assay

The level of VEGF in SWF samples was determined using a commercially available enzyme-linked immunosorbent assay (ELISA) that detects the soluble isoforms (VEGF 121 and VEGF 165) of human VEGF (R & D Systems, Minneapolis, MN). To directly compare the profile of VEGF with that of FGF-2, which is known to contribute to the angiogenic activity of SWF, we also measured FGF-2 levels using an ELISA directed at recombinant human FGF-2<sub>145</sub> (R & D Systems). Each sample was tested in duplicate, and results were averaged. Samples from each POD are presented as a group mean  $\pm$  SD. Results were analyzed for significance by a one-way analysis of variance followed by Tukey-Kramer multiple comparisons test.

### Endothelial Cell Migration

Endothelial cell chemotactic activity in response to SWF was measured as previously described.<sup>14</sup> Human dermal microvascular endothelial cells and growth medium were obtained from Cell Systems (Kirkland, WA). Endothelial cells in suspension were placed in the bottom wells of a 48-well blind well microchemotaxis chamber (Neuroprobe, Cabin John, MD) and overlaid with a gelatinized  $5\text{-}\mu\text{m}$  pore membrane. The top portion of the chamber was secured in place, and  $50\text{ }\mu\text{l}$  of test or control medium was dispensed into the top wells. The test medium contained recombinant VEGF or FGF-2 in amounts ranging from 1 to 50 ng/ml or wound fluid samples containing  $1\text{ }\mu\text{g}$  of total protein. Chambers were inverted and incubated for 2 hours at  $37^\circ\text{C}$ , after which the membranes were stained with Wright's Giemsa stain (Leukostat; Fisher Scientific, Chicago, IL). The number of endothelial cells that had migrated to the opposite surface of the membrane was counted in 10 random high-power fields. Each sample was tested in triplicate. Results are expressed as a mean number of endothelial cells migrated per 10 high-powered fields  $\pm$  SD. Chemotactic activity of individual samples was compared with control medium using a Student's *t*-test and Bonferroni postcomparison testing. *P* values less than 0.05 were considered significant.

### Bioassay for Angiogenic Activity

Assays of angiogenic activity were performed in the avascular cornea of the rat eye as previously de-

scribed.<sup>15</sup> Briefly, wound fluids containing approximately 5  $\mu$ g of total protein were incorporated 1:1 into noninflammatory Hydron polymer (Interferon Sciences, New Brunswick, NJ), and 5- $\mu$ l pellets were implanted into the corneal stroma 1 to 1.5 mm from the limbus. Corneas were examined daily with a stereomicroscope to monitor capillary growth by blinded observers. Responses showing sustained ingrowth of a brush-like network of capillary sprouts were judged to be positive, whereas responses showing no growth or only occasional sprouts were considered negative. Individual wound fluid samples were tested in multiple corneas and were considered angiogenic if more than 50% of the corneas showed a positive angiogenic response. Positive controls included VEGF (25 ng) and FGF-2 (50 ng). Dulbecco's modified Eagle's medium was used as a negative control. Five to 7 days after implantation some rats underwent intra-arterial perfusion with colloidal carbon to provide a permanent record of individual responses. Corneas were then excised, fixed in 2% glutaraldehyde-2.5% paraformaldehyde, flattened, and photographed.

#### Neutralization of VEGF

To determine the contribution of VEGF to the angiogenic activity of SWF, neutralizing antibody to VEGF was combined with SWF before addition to *in vitro* and *in vivo* assays. Antibody directed against recombinant human VEGF<sub>165</sub> was obtained from R & D Systems. 250 ng of anti-VEGF antibody was incubated with SWF or 25 ng of human recombinant VEGF (R & D Systems) for 30 minutes at 37°C before testing.

#### Immunohistochemistry

Samples of healing wounds were obtained by excising old biopsy sites from the pathological specimens of four patients undergoing mastectomy. Each patient had undergone an excisional biopsy before mastectomy, and each biopsy specimen had been determined to have tumor-free margins. Full thickness skin and subcutaneous tissue samples were embedded in OCT and sectioned perpendicular to the healing incision line. Immunostaining was performed using an avidin-biotin technique (Vector Laboratories, Burlingame, CA). Slides were fixed in cold acetone for 20 minutes followed by treatment with 3% peroxide in 0.1 mol/L Tris for 5 minutes to block endogenous peroxidase activity. All subsequent incubations were performed at 37°C in a humidified chamber unless otherwise noted. Tissue were pretreated with 3% horse serum in phosphate-buffered saline (PBS) for 30 minutes, incubated with anti-human VEGF mAb (gift of Dr. Napoleone Ferrara, Genentech, South San Francisco, CA), anti-human Leu-M5 (CD11c) (Becton Dickinson, San Jose, CA), or mouse IgG1 control for 45 minutes, and washed twice in PBS. Slides were then incubated with a 1:200 dilution of anti-mouse biotinylated antibody in PBS containing 3% horse serum, washed twice with PBS, incubated with avidin-conjugated horseradish peroxidase complex at room temperature for 20




Figure 1. VEGF levels in surgical drain fluid. Surgical drain fluid was collected as described in the text and VEGF levels determined by ELISA. VEGF levels were lowest on postoperative day 0 and rose steadily to peak on postoperative day 7. The sample sizes are as follows: day 0,  $n = 8$ ; day 1,  $n = 10$ ; day 2,  $n = 10$ ; day 3,  $n = 8$ ; day 4,  $n = 8$ ; day 5,  $n = 5$ ; day 6,  $n = 6$ ; and day 7,  $n = 2$ . On days 4, 6, and 7, fluids contained significantly more VEGF than fluids on day 0 ( $P < 0.05$ ).

minutes, and washed twice with PBS. Slides were then incubated with diaminobenzidine tetrahydrochloride substrate for 5 minutes at room temperature, rinsed in tap water, counterstained with Harris' hematoxylin, and dipped in saturated lithium carbonate solution for bluing. Serial sections were examined to assess the cell types expressing antigenic VEGF.


#### Results

##### VEGF Levels in SWF

The level of VEGF in 57 SWF samples was measured by ELISA (Figure 1). Normal serum contained on average  $0.4 \pm 0.2$  ng/ml VEGF. SWF levels on POD 0 were slightly higher than serum averaging  $1.0 \pm 1.0$  ng/ml. VEGF levels increased to  $3.9 \pm 2.7$  ng/ml on POD 3 and were highest by POD 7 at  $6.9 \pm 1.3$  ng/ml. This steady rise in VEGF levels over time was similar in both mastectomy and neck wounds and was unchanged when samples were corrected for total protein content. Although tumors have been shown to produce VEGF, residual tumor is unlikely to be the source of the VEGF for two reasons. First, the margins on all sites were determined to be free of tumor by a surgical pathologist. Second, the VEGF did not appear in the fluid until several days after surgery, suggesting that new synthesis was initiated at the site of injury.

##### FGF-2 Levels in SWF

To directly compare the profile of VEGF and FGF-2 in surgical wounds, the level of FGF-2 in 25 SWF samples was also measured. While VEGF is lowest on POD 0 and then rises over several days, FGF-2 levels were highest on POD 0 at  $765 \pm 436$  pg/ml and then fell rapidly over the next 1 to 2 days (Figure 2). Both mastectomy and




**Figure 2.** FGF-2 levels in surgical drain fluid. Surgical drain fluid FGF-2 levels were measured by ELISA. In contrast to VEGF, the level of FGF-2 in surgical drain fluid is highest on postoperative day 0 and then falls quickly to near serum levels by postoperative day 2. The sample sizes are as follows: day 0,  $n = 8$ ; day 1,  $n = 8$ ; day 2,  $n = 7$ ; day 3,  $n = 7$ ; day 4,  $n = 5$ ; day 5,  $n = 4$ ; day 6,  $n = 4$ ; and day 7,  $n = 1$ . On day 0, fluid contained significantly more FGF-2 than all other days ( $P < 0.001$ ).

neck dissection wounds demonstrated similar FGF-2 profiles. These results are similar to our previous report.<sup>8</sup>

#### VEGF-Mediated Activity in Surgical Wound Fluid — Endothelial Cell Migration

The endothelial cell chemotactic activity of seven random SWF samples from postoperative days 0, 3, and 6 was determined using a modified Boyden chamber. SWF samples from all 3 days stimulated marked endothelial cell chemotaxis compared with basal media (Figure 3;  $P < 0.01$  for all samples). The addition of anti-VEGF neutralizing antibody did not affect the chemotactic activity of two SWF samples from POD 0 (average decrease in activity  $12 \pm 6\%$ ). Anti-VEGF antibody lowered the



**Figure 3.** VEGF-mediated endothelial cell chemotactic activity of surgical drain fluid. Fluid from surgical wounds was tested for endothelial cell chemotactic activity in a modified Boyden chamber as described in the text. Random samples from POD 0 through 6 consistently demonstrated marked chemotactic activity compared with control media ( $P < 0.01$  for each). Anti-VEGF antibody markedly diminished the chemotactic activity of recombinant VEGF (25 ng) and of five samples from POD 3 and 6 but did not alter the activity of two samples from POD 0.

**Table 1.** Effect of Anti-VEGF Antibody on Angiogenic Activity of Wound Fluid

Surgical wound fluid sample	Rat corneal neovascularization: proportion of positive responses (%)	
	No treatment	+ Anti-VEGF antibody
Postoperative day 0		
Mastectomy 1	2 of 2 (100)	2 of 2 (100)
Neck dissection 2	2 of 2 (100)	2 of 2 (100)
Postoperative day 3		
Mastectomy 3	3 of 3 (100)	0 of 3 (0)
Mastectomy 4	2 of 2 (100)	1 of 3 (33)
Mastectomy 5	3 of 3 (100)	nd
Mastectomy 6	2 of 2 (100)	nd
Postoperative day 4		
Mastectomy 7	3 of 3 (100)	nd
Postoperative day 6		
Neck dissection 2	3 of 3 (100)	0 of 3 (0)
Neck dissection 3	3 of 3 (100)	0 of 2 (0)
Mastectomy 4	2 of 2 (100)	1 of 4 (25)
Controls		
DMEM*	0 of 3 (0)	0 of 3 (0)
VEGF (25 ng)	3 of 3 (100)	1 of 4 (25)

\*DMEM, Dulbecco's modified Eagle's medium; nd, not done.


chemotactic activity of five samples from POD 3 and 6 by an average of  $76 \pm 13\%$  (Figure 3). VEGF-mediated endothelial cell chemotactic activity therefore parallels VEGF protein levels in SWF. While VEGF appears to be the primary chemotactic agent by the third postoperative day, it does not contribute significantly to the activity of POD 0 SWF.

#### VEGF-Mediated Activity in Surgical Wound Fluid — In Vivo Angiogenic Activity

SWF samples from POD 0, 1, 3, and 6 stimulated angiogenesis in the avascular rat cornea assay (Table 1, Figure 4A). The neovascular response was uniform across different postoperative days, generally occurring rapidly and without an excessive inflammatory response. Similar to the results reported above, anti-VEGF antibody did not affect the *in vivo* angiogenic response to two POD 0 samples but significantly reduced the angiogenic activity of five of five SWF samples from POD 3 and 6 (Table 1, Figure 4B). VEGF therefore mediates in large part the chemotactic and angiogenic activity of SWF from postoperative days 3 and 6 but not of fluid from postoperative day 0.

#### Source of VEGF in Wound Biopsies

Healing breast biopsy sites were analyzed with immunohistochemical staining to identify the source of wound VEGF. Four samples were obtained from 7 to 22 days after initial biopsy. Compared with control skin, staining for VEGF was substantially increased at wound sites. In wounds, VEGF staining was mainly localized to fibroblasts and macrophages (Figure 5). Normal skin from adjacent uninjured areas of the breast demonstrated minimal staining for VEGF. This staining was localized to



**Figure 4.** Rat corneal neovascularization in response to mastectomy drain fluid from postoperative day 6. Dense new vessel ingrowth from the corneal limbus toward a pellet containing drain fluid is demonstrated (A). Addition of neutralizing anti-VEGF antibody (B) dramatically diminished the response to wound fluid.

fibroblasts. Normal skin macrophages were generally negative for VEGF. Neutrophils, lymphocytes, endothelial cells, and mast cells were generally immunonegative for VEGF in both wounds and normal skin.

### Discussion

VEGF has been associated with angiogenesis in numerous pathological situations, including tumor growth, proliferative retinopathy, and rheumatoid arthritis.<sup>16-18</sup> In particular, a great amount of interest has centered on the role of VEGF in the growth and metastasis of several tumor types and on the potential role of inhibitors of VEGF in antitumor therapy.<sup>16,19</sup> This interest was borne in part from the original description of VEGF as a potent vascular permeability factor, a property that was thought to contribute to tumor metastases.<sup>20,21</sup>


Increased vascular permeability has since been shown to occur during the early phases of wound repair, theoretically allowing deposition of the fibrin-rich matrix necessary for cellular migration.<sup>22,23</sup> The identification of increased vascular permeability concomitant with increased VEGF production in skin wounds provided evidence for a role for VEGF in wound repair.<sup>12</sup> However, VEGF-mediated angiogenic activity in wounds had remained speculative.

Our results provide two lines of evidence to support a central role for VEGF in mediating angiogenesis in surgical wounds. First, VEGF is produced or released locally in wounds during a time when new vessel growth is initiated and maintained. Second, neutralization of VEGF greatly decreases the angiogenic and endothelial cell chemotactic activity of surgical wound fluid. In the current study, VEGF levels in wound fluid rose steadily through the first week after injury. New vessel formation in healing wounds follows a similar time course with newly formed vessels first evident 2 to 3 days after injury with maximal evidence at 1 to 2 weeks.<sup>24</sup> By postoperative day 3, VEGF appears to be the primary angiogenic mediator in SWF as addition of neutralizing antibody eliminated most of the chemotactic and angiogenic activity of all samples tested. The current study does not examine how wound proteases may influence the levels of bioactive FGF-2 and VEGF. Wound fluid has been described to contain high levels of proteases, such as metalloproteinases.<sup>25</sup> Although we did not examine the levels of protease activity in our samples, our results suggest that the protease activity in wound fluid is not sufficient to eliminate bioactive growth factors such as FGF-2 and VEGF.

To our knowledge this report is the first direct evidence of VEGF-mediated angiogenic activity in human surgical wounds. VEGF may contribute to the angiogenic stimulus in wounds either by direct effects on proliferating and migrating endothelial cells or indirectly by effecting persistent vascular permeability at the level of existing microvessels. Mitigation of endothelial cell chemotactic activity of SWF by anti-VEGF antibody suggests that at least part of the stimulus provided by VEGF in the surgical wound is direct.

Our results demonstrate that the primary sources of surgical wound VEGF are the fibroblast and the macrophage. Both cell types have been described to produce VEGF *in vitro*.<sup>26,27</sup> Previous studies by Brown et al<sup>12</sup> also identified macrophage-like cells as a source of VEGF in mouse skin wounds but found keratinocytes to be the major source of VEGF. Keratinocytes in healing breast biopsy sites did not stain for VEGF in our hands. This discrepancy between our results and those of Brown et al probably reflects the inherent differences between skin and deep surgical wounds. Keratinocytes would not be expected to contribute much to VEGF levels in deep surgical wounds because of the relatively small area of epidermal injury in these wounds.

While VEGF appears to be a primary angiogenic mediator in surgical wounds by several days postoperatively, it does not appear to participate in the initiation phase of angiogenesis. SWF obtained immediately after injury (POD 0) stimulates angiogenesis and chemotaxis but contains low levels of VEGF and is not affected by neutralizing anti-VEGF antibody. We have previously reported that FGF-2 accounts for a large part of the immediate angiogenic stimulus in SWF based on similar neutralization experiments.<sup>9</sup> FGF-2 levels peak within hours of injury and fall as VEGF levels start to rise. This pattern suggests that FGF-2 and VEGF act in concert to provide a sustained angiogenic stimulus in surgical wounds, as



**Figure 5.** Immunoperoxidase detection of antigenic VEGF in frozen human breast tissue. **A:** Breast biopsy site showing strong staining of both fibroblasts and macrophages. Magnification,  $\times 264$ . **B:** Higher power image of **A**, showing fibroblast staining. Magnification,  $\times 528$ . **C:** Higher power image of **A**, showing macrophage staining (arrows). Magnification,  $\times 1056$ . **D:** Normal breast skin showing minimal fibroblast staining. Magnification,  $\times 264$ . **E:** Higher power image of tissue in **D**, showing minimal fibroblast staining. Magnification,  $\times 528$ . **F:** Immunoperoxidase detection of Leu-M5 (CD11c), a macrophage marker, in a serial section to the tissue in **C**, showing staining in a similar pattern as the VEGF staining. Magnification,  $\times 1056$ .

the angiogenic stimulus initiated by FGF-2 is subsequently maintained by VEGF.

The FGF-2 and VEGF-mediated angiogenic responses in wounds may represent two components of an angiogenic cascade. FGF-2 is well suited to initiate angiogenesis because it is available immediately after injury and because it affects numerous cell types. Preformed FGF-2 that is sequestered in uninjured tissue is likely released at the time of surgery either by cell damage or by enzymes

such as thrombin.<sup>28-31</sup> Because multiple cell types carry the FGF receptor, soluble FGF-2 stimulates multiple early wound events, including the proliferation and migration of both endothelial cells and fibroblasts.<sup>32</sup> In this way angiogenesis and collagen deposition may be initiated while synthesis of mediators such as VEGF is beginning. Unlike the broadly distributed FGF-receptors, VEGF-receptors are almost exclusive to endothelium.<sup>33</sup> Transition to a predominantly VEGF-mediated angiogenic stimulus






Figure 6. A model of angiogenesis in the healing wound. Immediately after injury, FGF-2 is quickly released, providing an early stimulus for endothelial cell proliferation. As FGF-2 levels decline, VEGF is produced. VEGF provides a sustained stimulus for endothelial cell migration and differentiation into new capillary tubes. Capillary density reaches a maximum shortly after peak VEGF levels are observed. Capillary regression then begins either because of a lack of continued stimulus or through the direct effect of antiangiogenic mediators. The indicated time period for each event (provided in days) is representative of the sequence observed in both human wounds and in murine models of tissue repair.

might therefore allow more specific regulation of vessel growth and regression during proliferative and maturation phases of wound repair. Our results support a model of wound angiogenesis in which early endothelial proliferation is supported by FGF-2 and later capillary growth and differentiation is directed by VEGF (Figure 6). Such a model has support in *in vitro* systems as well, such as the rat aorta model of angiogenesis.<sup>34</sup> Whether or not VEGF persists as the primary mediator throughout the remainder of the repair process remains to be determined.

Regulation of the VEGF-mediated response in wounds may take many forms. FGF-2 appears to have a direct role in the VEGF response based on observations that FGF-2 can up-regulate VEGF production<sup>35</sup> and that FGF-2 and VEGF act synergistically in stimulating angiogenesis in some models.<sup>36,37</sup> Several other growth factors such as platelet derived growth factor and transforming growth factor- $\beta$  may also regulate VEGF production.<sup>38,39</sup> One interesting possible mediator of VEGF activity in wounds is local hypoxia. VEGF has a well-described hypoxia-inducible element that is thought to account for its increased production in ischemic retinopathy, myocardial ischemia, and in areas of tumor necrosis.<sup>11,16</sup> Extensive work by Hunt and others<sup>40,41</sup> has demonstrated that wounds are characteristically hypoxic during early phases of repair and that angiogenic activity in wounds varies inversely with wound oxygen levels. VEGF has been proposed as a mediator of this effect.<sup>42,43</sup> In theory, VEGF production and VEGF-mediated angiogenic activity would rise in the early hypoxic wound and then fall when neovascularization is complete and wound perfusion is restored.

While our results describe the initiation of a VEGF-mediated response, additional work is required to understand the regression of the vasculature that is seen in resolving wounds. Taken together, the elucidation of the

mechanisms responsible for initiating and driving the angiogenic response in wounds might find broad application in areas such as the augmentation of wound repair, improving collateralization of ischemic limbs and myocardium, and understanding tumor growth.

## Acknowledgment

We thank Dr. George K. Haines III for his review of the immunohistochemical staining.

## References

1. Battegay J: Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. *J Mol Med* 1995, 73:333-346
2. Schilling JA, Favata BV, Radakovich M: Studies of fibroplasia in wound healing. *Surg Gynecol Obstet* 1953, 96:143-149
3. Orredson SU, Knighton MD, Scheuenstuhl H, Hunt TK: A quantitative *in vitro* study of fibroblast, and endothelial cell migration in response to serum, and wound fluid. *J Surg Res* 1983, 35:249-258
4. Reed MJ, Puolakkainen P, Lane TF, Dickerson D, Bornstein P, Sage EH: Differential expression of SPARC and thrombospondin 1 in wound repair: immunolocalization and *in situ* hybridization. *J Histochem Cytochem* 1993, 41:1467-1477
5. DiPietro LA, Nissen NN, Gamelli RL, Koch AE, Pyle JM, Polverini PJ: Thrombospondin 1 synthesis, and function in wound repair. *Am J Pathol* 1996, 148:1861-1869
6. Clark, AF: Wound repair: overview and general considerations. *The Molecular and Cellular Biology of Wound Repair*. Edited by AF Clark. New York, Plenum Press, 1996
7. Martin P: Wound healing: aiming for perfect skin regeneration. *Science* 1997, 276:75-81
8. Nissen NN, Polverini PJ, Gamelli RL, DiPietro LA: Basic fibroblast growth factor mediates angiogenic activity in early surgical wounds. *Surgery* 1996, 119:459-465
9. Katz MH, Alvarez AF, Kirsner RS, Eaglstein WH, Falanga V: Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growth. *J Am Acad Dermatol* 1991, 25:1054-1058
10. Ferrara N, Houck K, Jakeman L, Leung D: Molecular and biological properties of the vascular endothelial growth factor family of proteins. *Endocr Rev* 1992, 13:18-32
11. Dvorak HF, Brown LF, Detmar M, Dvorak AM: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. *Am J Pathol* 1995, 146:1029-1039
12. Brown LF, Kiang-Tec Y, Berse B, Yeo T, Senger DR, Dvorak HF, Van De Water L: Expression of vascular permeability factor (vascular endothelial growth factor) by epidermal keratinocytes during wound healing. *J Exp Med* 1992, 176:1375-1379
13. Frank S, Hubner G, Breier G, Longaker MR, Greenhalgh DG, Werner S: Regulation of vascular endothelial growth factor expression in cultured keratinocytes. *J Biol Chem* 1995, 270:12607-12613
14. DiPietro LA, Nebgen DR, Polverini PJ: Downregulation of endothelial cell thrombospondin 1 enhances *in vitro* angiogenesis. *J Vasc Res* 1994, 31:178-185
15. Polverini PJ, Leibovich SJ: Induction of neovascularization *in vivo* and endothelial cell proliferation *in vitro* by tumor-associated macrophages. *Lab Invest* 1984, 51:635-642
16. Senger DR, Van De Water L, Brown L, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM, Dvorak HF: Vascular permeability factor (VPF, VEGF) in tumor biology. *Cancer Metastasis Rev* 1993, 12:303-324
17. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE, Nguyen HV, Aiello LE, Ferrara N, King GL: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorder. *N Engl J Med* 1994, 331:1480-1487
18. Fava R, Olsen N, Spencer-Green G, Yeo KT, Yeo TK, Berse B, Jackman R, Senger D, Dvorak H, Brown L: Vascular permeability factor/endothelial growth factor (VPF/VEGF): accumulation and ex-

- pression in human synovial fluids and rheumatoid synovial tissue. *J Exp Med* 1994; 180:341-346
19. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. *Nature* 1993; 362:841-844
20. Senger DR, Galli SJ, Dvorak AM, Peruzzi CA, Harvey VS, Dvorak HF: Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. *Science* 1983; 219:983-985
21. Senger DR, Peruzzi CA, Feder J, and Dvorak HF: A highly conserved vascular permeability factor secreted by a variety of human and rodent tumor cell lines. *Cancer Res* 1986; 46:5629-5632
22. Brown LF, Van De Water L, Harvey VS, Dvorak HF: Fibrinogen influx and accumulation of cross-linked fibrin in healing wounds and in tumor stroma. *Am J Pathol* 1988; 130:455-465
23. Breuing K, Eriksson E, Liu P, Miller DR: Healing of partial thickness porcine skin wounds in a liquid environment. *J Surg Res* 1992; 52:50-58
24. Ross R, Benditt EP: Wound healing and collagen production: fine structure in experimental scurvy. *J Cell Biol* 1962; 12:533-554
25. Wysocki AB, Staiano-Coico L, Grinnell F: Wound fluid from chronic leg ulcers contains elevated levels of metalloproteinases MMP-2 and MMP-9. *J Invest Dermatol* 1993; 101:64-68
26. Berse B, Brown LF, Van De Water L, Dvorak HF, Senger DR: Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. *Mol Bio Cell* 1992; 3:211-220
27. Ben-Av P, Croxford LJ, Wilder R L, Hla T: Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. *FEBS Lett* 1995; 372:83-87
28. Cordon-Cardo C, Vlodavsky I, Haimovitz-Fredman A, Hicklin AD, Fuks Z: Expression of basic fibroblast growth factor in normal human tissues. *Lab Invest* 1990; 63:832-840
29. Muthukrishnan L, Warder E, McNeil P: Basic fibroblast growth factor is efficiently released from a cytosolic storage site through plasma membrane disruptions of endothelial cells. *J Cell Physiol* 1991; 148: 1-16
30. Ben-Ezra M, Vlodavsky I, Ishai-Michaeli R, Neufeld G, Bar-Shavit R: Thrombin-induced release of active basic fibroblast growth factor-heparan sulfate complexes from subendothelial extracellular matrix. *Blood* 1993; 81:3324-3331
31. Vallaschi S, Nicosia RF: Angiogenic role of endogenous basic fibroblast growth factor released by rat aorta after injury. *Am J Pathol* 1993; 143:181-190
32. Abraham JA, Klagsbrun M: Modulation of wound repair by members of the fibroblast growth factor family. *The Molecular and Cellular Biology of Wound Repair*. Edited by AF Clark. New York, Plenum Press, 1996
33. Olander JV, Connolly DT, DeLarco JE: Specific binding of vascular permeability factor to endothelial cells. *Biochem Biophys Res Commun* 1991; 175:68-76
34. Nicosia RF, Lin YJ, Hazellon D, Qian XH: Endogenous regulation of angiogenesis in the rat aorta model. *Am J Pathol* 1997; 151:1379-1386
35. Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD: Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells: synergistic interaction with hypoxia. *Circulation* 1995; 92:11-14
36. Koolwijk P, van Erck MG, de Vree WJ, Vermeer MA, Weich HA, Hanemaaijer R, van Hinsbergh VW: Cooperative effects of TNF $\alpha$ , bFGF, and VEGF on the formation of tubular structures of human microvascular endothelial cells in a fibrin matrix: role of urokinase activity. *J Cell Biol* 1996; 32:1177-1188
37. Asahara T, Bauters C, Zheng LP, Takeshita S, Bunting S, Ferrara N, Symes JF, Isner JM: Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo. *Circulation* 1995; 92:11365-11371
38. Pertovarra L, Kaipainen A, Mustoe T, Orpana A, Ferrara N, Saksela O, Alitalo K: Vascular endothelial growth factor is induced in response to transforming growth factor- $\beta$  in fibroblastic and epithelial cells. *J Biol Chem* 1994; 269:6271-6274
39. Dolecki GJ, Connolly DT: Effects of a variety of cytokines and inducing agents on vascular permeability factor mRNA levels in U937 cells. *Biochem Biophys Res Commun* 1991; 180:572-578
40. Knighton DR, Silver IA, Hunt TK: Regulation of wound-healing angiogenesis: effect of oxygen gradients and inspired oxygen concentration. *Surgery* 1981; 90:262-270
41. Hunt TK, Twomey P, Zederfeldt B, Dunphy JE: Respiratory gas tensions and pH in healing wounds. *Am J Surg* 1967; 114:302-307
42. Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-induced angiogenesis. *Nature* 1992; 359:843-845
43. Detmar M, Brown LF, Berse B, Jackman RW, Elicker BM, Dvorak HF, Claffey KP: Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin. *J Invest Dermatol* 1997; 108:263-268